文献速递介入腹部CTDSA

经导管动脉化疗栓塞联合同步锥形束CT引导微波消融治疗小肝癌:50例操作临床经验

Transcatheter Arterial Chemoembolization Combined with Simultaneous Cone-beam Computed Tomography-guided Microwave Ablation in the Treatment of Small Hepatocellular Carcinoma: Clinical Experiences From 50 Procedures.
PubMed 文献 · Acad Radiol · 2020-10-13

回顾性分析50例患者66个病灶,接受TACE联合同步CBCT引导MWA治疗小肝癌,全部技术成功,1、3、5年PFS率分别为90.0%、65.4%、35.7%,OS率分别为98.0%、89.8%、74.3%,无重大并发症,单发肿瘤直径小于3cm是PFS和OS的独立保护因素(p<0.001)。

要点

  • CBCT引导同步TACE联合MWA治疗小肝癌技术成功率高,平均安全 margin 1.4±0.6 cm
  • 单发肿瘤直径小于3 cm是PFS和OS的独立保护因素(p<0.001)
  • 无重大并发症,轻微并发症包括无症状肝周积液、大量右侧胸腔积液需引流、肝包膜下出血需栓塞

核心结论

  • CBCT引导的TACE联合同步MWA是治疗小肝癌安全且成功的治疗方法,具有高技术疗效。

研究设计与样本

  • 回顾性分析50例患者(38男,12女)的66个病灶,接受TACE联合同步CBCT引导MWA治疗小肝癌。
  • 治疗后1个月采用mRECIST标准评估肿瘤反应,并记录介入相关并发症及肝肾功能变化,计算无进展生存期(PFS)和总生存期(OS)。

诊断标准与关键数值

  • 平均靶肿瘤大小为3.4±0.7 cm(范围2.2-4.9 cm)。
  • 平均能量51.3±8.4 kJ,每肿瘤平均消融时间6.7±0.8分钟,平均安全 margin 1.4±0.6 cm。
  • 1、3、5年PFS率分别为90.0%、65.4%、35.7%,平均PFS 43.46个月;1、3、5年OS率分别为98.0%、89.8%、74.3%,平均OS 54.90个月。
  • 多因素Cox回归分析显示,TACE联合MWA治疗单发肿瘤直径小于3 cm是PFS和OS的独立保护因素(p<0.001)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To investigate the technical success, safety and outcomes of transcatheter arterial chemoembolization (TACE) combined with simultaneous cone-beam computed tomography (CBCT)-guided microwave ablation (MWA) in small hepatocellular carcinoma (SHCC).

MATERIALS AND METHODS: Retrospective analysis of 66 lesions in 50 patients (38 men, 12 women) who underwent TACE combined with simultaneous CBCT-guided MWA for SHCC. After 1 month of treatment, the tumor responses were assessed using the mRECIST criteria, along with interventional-related complications and changes in hepatic and renal function. Moreover, progression-free survival (PFS) and overall survival (OS) were calculated.

RESULTS: All patients achieved technical success. The mean target tumor size was 3.4 ± 0.7 (range, 2.2-4.9) cm. The mean energy, ablation duration per tumor, and the mean safety margin were 51.3 ± 8.4 kJ, 6.7 ± 0.8 minutes and 1.4 ± 0.6 cm, respectively. The 1-, 3-, and 5-year PFS rates were 90.0%, 65.4%, and 35.7%, respectively, with a mean PFS of 43.46 months; and the 1-, 3-, and 5-year OS rates were 98.0%, 89.8%, and 74.3%, respectively, with a mean OS of 54.90 months. Multivariate Cox regression analysis further illustrated that TACE combined with MWA in the treatment of a single tumor with a diameter of less than 3 cm was an independent protective factor for PFS and OS (p < 0.001). The patients had no major complications. Among the exceptions, one patient (2%) had an asymptomatic perihepatic effusion that resolved spontaneously, two patients (4%) developed massive right pleural effusion, requiring thoracic drainage, and another patient (2%) developed a hepatic subcapsular hemorrhage required interventional embolization.

CONCLUSION: CBCT-guided TACE combined with simultaneous MWA was a safe and successful treatment of SHCC with a high technical efficacy.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Li Z, Hao D, Jiao D, et al. Transcatheter Arterial Chemoembolization Combined with Simultaneous Cone-beam Computed Tomography-guided Microwave Ablation in the Treatment of Small Hepatocellular Carcinoma: Clinical Experiences From 50 Procedures. Acad Radiol. 2020. PMID: 33060007. doi:10.1016/j.acra.2020.08.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。